Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: A long-term retrospective cohort study

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Kawashima, Masatoshi ^a   Wada, Koji ^a   Ohta, Hiroshi ^a   Terawaki, Hiroyuki ^b   Aizawa, Yoshiharu ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

chronic kidney disease; cohort; glomerular filtration rate; hyperuricemia; Japan

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERURICEMIA; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; OBESITY; RETROSPECTIVE STUDY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ASYMPTOMATIC DISEASES; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; HYPERURICEMIA; INDUSTRY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79959753936     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-31     Document Type: Article

References (40)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 2 Suppl 1 1 266 11904577
2. Prevalence of chronic kidney disease in the United States. J Coresh E Selvin LA Stevens J Manzi JW Kusek P Eggers F Van Lente AS Levey, JAMA 2007 298 17 2038 2047 10.1001/jama.298.17.2038 17986697 (Pubitemid 350074801)
3. Prevalence of chronic kidney disease in the Japanese general population. E Imai M Horio T Watanabe K Iseki K Yamagata S Hara N Ura Y Kiyohara T Moriyama Y Ando S Fujimoto T Konta H Yokoyama H Makino A Hishida S Matsuo, Clin Exp Nephrol 2009 13 6 621 630 10.1007/s10157-009-0199-x 19513802
4. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. WG Walker JD Neaton JA Cutler R Neuwirth JD Cohen, JAMA 1992 268 21 3085 3091 10.1001/jama.268.21.3085 1433739
5. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. GL Bakris M Williams L Dworkin WJ Elliott M Epstein R Toto K Tuttle J Douglas W Hsueh J Sowers, Am J Kidney Dis 2000 36 3 646 661 10.1053/ajkd.2000.16225 10977801
6. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. K Yamagata K Ishida T Sairenchi H Takahashi S Ohba T Shiigai M Narita A Koyama, Kidney Int 2007 71 2 159 166 10.1038/sj.ki.5002017 17136030 (Pubitemid 46094690)
7. Predictors of new-onset kidney disease in a community-based population. CS Fox MG Larson EP Leip B Culleton PW Wilson D Levy, JAMA 2004 291 7 844 850 10.1001/jama.291.7.844 14970063 (Pubitemid 38543772)
8. Blood pressure predicts risk of developing end-stage renal disease in men and women. M Tozawa K Iseki C Iseki K Kinjo Y Ikemiya S Takishita, Hypertension 2003 41 6 1341 1345 10.1161/01.HYP.0000069699.92349.8C 12707291 (Pubitemid 36706087)
9. Effect of blood pressure on early decline in kidney function among hypertensive men. S Vupputuri V Batuman P Muntner LA Bazzano JJ Lefante PK Whelton J He, Hypertension 2003 42 6 1144 1149 10.1161/01.HYP.0000101695.56635. 31 14597644 (Pubitemid 37549069)
10. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). AI Adler RJ Stevens SE Manley RW Bilous CA Cull RR Holman, Kidney Int 2003 63 1 225 232 10.1046/j.1523-1755. 2003.00712.x 12472787 (Pubitemid 35463925)
11. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. S Araki M Haneda T Sugimoto M Isono K Isshiki A Kashiwagi D Koya, Diabetes 2005 54 10 2983 2987 10.2337/diabetes.54.10.2983 16186402 (Pubitemid 41401096)
12. Preventing microalbuminuria in type 2 diabetes. P Ruggenenti A Fassi AP Ilieva S Bruno IP Iliev V Brusegan N Rubis G Gherardi F Arnoldi M Ganeva B Ene-Iordache F Gaspari A Perna A Bossi R Trevisan AR Dodesini G Remuzzi, N Engl J Med 2004 351 19 1941 1951 10.1056/NEJMoa042167 15516697 (Pubitemid 39447135)
13. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. S Andersen J Brochner-Mortensen HH Parving, Diabetes Care 2003 26 12 3296 3302 10.2337/diacare.26.12.3296 14633817 (Pubitemid 37466890)
14. Cholesterol and the risk of renal dysfunction in apparently healthy men. ES Schaeffner T Kurth GC Curhan RJ Glynn KM Rexrode C Baigent JE Buring JM Gaziano, J Am Soc Nephrol 2003 14 8 2084 2091 12874462 (Pubitemid 36909916)
15. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. P Muntner J Coresh JC Smith J Eckfeldt MJ Klag, Kidney Int 2000 58 1 293 301 10.1046/j.1523-1755.2000.00165.x 10886574 (Pubitemid 30429874)
16. Body mass index and the risk of development of end-stage renal disease in a screened cohort. K Iseki Y Ikemiya K Kinjo T Inoue C Iseki S Takishita, Kidney Int 2004 65 5 1870 1876 10.1111/j.1523-1755.2004.00582.x 15086929 (Pubitemid 38591038)
17. Elevated uric acid increases the risk for kidney disease. RP Obermayr C Temml G Gutjahr M Knechtelsdorfer R Oberbauer R Klauser-Braun, J Am Soc Nephrol 2008 19 12 2407 2413 10.1681/ASN.2008010080 18799720
18. Uric acid and long-term outcomes in CKD. M Madero MJ Sarnak X Wang T Greene GJ Beck JW Kusek AJ Collins AS Levey V Menon, Am J Kidney Dis 2009 53 5 796 803 10.1053/j.ajkd.2008.12.021 19303683
19. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. K Iseki Y Ikemiya T Inoue C Iseki K Kinjo S Takishita, Am J Kidney Dis 2004 44 4 642 650 15384015 (Pubitemid 39237608)
20. Serum uric acid and renal prognosis in patients with IgA nephropathy. I Ohno T Hosoya H Gomi K Ichida H Okabe M Hikita, Nephron 2001 87 4 333 339 10.1159/000045939 11287777 (Pubitemid 32260834)
21. Revised equations for estimated GFR from serum creatinine in Japan. S Matsuo E Imai M Horio Y Yasuda K Tomita K Nitta K Yamagata Y Tomino H Yokoyama A Hishida, Am J Kidney Dis 2009 53 6 982 992 10.1053/j.ajkd.2008.12.034 19339088
22. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. S Hallan A Asberg M Lindberg H Johnsen, Am J Kidney Dis 2004 44 1 84 93 10.1053/j.ajkd.2004.03.027 15211442 (Pubitemid 38880931)
23. Regression Models and Life-Tables. D Cox, J R Stat Soc Ser B 1972 34 2 187 220
24. Nonparametric Estimation from Incomplete Observations. EL Kaplan P Meier, J Am Stat Assoc 1958 53 282 457 481 10.2307/2281868
25. SPSS. SPSS for Windows VJ, Chicago: SPSS Inc 2008
26. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. YP Siu KT Leung MK Tong TH Kwan, Am J Kidney Dis 2006 47 1 51 59 10.1053/j.ajkd.2005.10.006 16377385 (Pubitemid 41828266)
27. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. F Perez-Ruiz M Calabozo AM Herrero-Beites G Garcia-Erauskin JI Pijoan, Nephron 2000 86 3 287 291 10.1159/000045783 11096285
28. Guideline for the management of hyperuricemia and gout (in Japanese). Japanese Society of Gout and Nucleic Acid Metabolosm 2002
29. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. M Ravid D Brosh D Ravid-Safran Z Levy R Rachmani, Arch Intern Med 1998 158 9 998 1004 10.1001/archinte.158.9.998 9588433 (Pubitemid 28213577)
30. Analysis of metabolic parameters as predictors of risk in the RENAAL study. GB Appel J Radhakrishnan MM Avram RA DeFronzo F Escobar-Jimenez MM Campos E Burgess DA Hille TZ Dickson S Shahinfar BM Brenner, Diabetes Care 2003 26 5 1402 1407 10.2337/diacare.26.5.1402 12716796 (Pubitemid 36929170)
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 25 3143 3421 12485966
32. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. T Teramoto J Sasaki H Ueshima G Egusa M Kinoshita K Shimamoto H Daida S Biro K Hirobe T Funahashi K Yokote M Yokode, J Atheroscler Thromb 2007 14 4 155 158 10.5551/jat.E537 17827859
33. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. K Reynolds D Gu P Muntner JW Kusek J Chen X Wu X Duan CS Chen MJ Klag PK Whelton J He, J Am Soc Nephrol 2007 18 6 1928 1935 10.1681/ASN.2006111199 17475822 (Pubitemid 46870330)
34. Blood pressure and end-stage renal disease in men. MJ Klag PK Whelton BL Randall JD Neaton FL Brancati CE Ford NB Shulman J Stamler, N Engl J Med 1996 334 1 13 18 10.1056/NEJM199601043340103 7494564 (Pubitemid 26012498)
35. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr DW Jones BJ Materson S Oparil JT Wright EJ Roccella Jr, Hypertension 2003 42 6 1206 1252 10.1161/01.HYP.0000107251.49515.c2 14656957 (Pubitemid 37553153)
36. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). T Ogihara K Kikuchi H Matsuoka T Fujita J Higaki M Horiuchi Y Imai T Imaizumi S Ito H Iwao K Kario Y Kawano S Kim-Mitsuyama G Kimura H Matsubara H Matsuura M Naruse I Saito K Shimada K Shimamoto H Suzuki S Takishita N Tanahashi T Tsuchihashi M Uchiyama S Ueda H Ueshima S Umemura T Ishimitsu H Rakugi, Hypertens Res 2009 32 1 3 107 19300436
37. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. G Remuzzi A Benigni A Remuzzi, J Clin Invest 2006 116 2 288 296 10.1172/JCI27699 16453013 (Pubitemid 43228342)
38. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. H Kramer A Luke A Bidani G Cao R Cooper D McGee, Am J Kidney Dis 2005 46 4 587 594 10.1053/j.ajkd.2005.06.007 16183412 (Pubitemid 41383936)
39. Guideline for the Treatment of Obesity (in Japanese). Japan Society for the Study of Obesity 2006
40. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. E Imai M Horio K Nitta K Yamagata K Iseki Y Tsukamoto S Ito H Makino A Hishida S Matsuo, Am J Kidney Dis 2007 50 6 927 937 10.1053/j.ajkd.2007.09.004 18037093 (Pubitemid 350130278)